Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target messenger RNAs with partial complementarity to B7 homolog 3 (B7-H3) short hairpin RNA (shRNA) seed region refer to a diverse set of unintended genetic transcripts that are downregulated during the use of RNA interference (RNAi) tools directed against B7-H3 (CD276). This phenomenon is driven by the 'seed region' of the shRNA guide strand (nucleotides 2–8), which can bind to the 3' untranslated regions (UTRs) of non-target mRNAs with partial complementarity, mimicking the action of endogenous microRNAs (Jackson et al., 2003; Birmingham et al., 2006). B7-H3 is a member of the B7 family of immunoregulatory proteins and is a significant target in oncology due to its overexpression in various solid tumors and its role in inhibiting T-cell mediated immune responses (NCBI Gene ID: 80381). However, research utilizing shRNAs to knock down B7-H3 has often encountered 'off-target toxicity,' where the observed phenotypic changes—such as reduced cell proliferation or increased apoptosis—are actually caused by the unintended silencing of these off-target mRNAs rather than the loss of B7-H3 itself (Lin et al., 2019). This highlights a critical challenge in functional genomics and the development of RNAi-based therapeutics, necessitating rigorous validation through rescue experiments or the use of multiple independent shRNA sequences to ensure specificity. These off-target interactions are not therapeutic goals but represent technical artifacts that can lead to false-positive results in drug target validation studies.
Unintended sequence-specific downregulation of mRNAs via the RNA-induced silencing complex (RISC) triggered by seed-region complementarity in the 3' UTR.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNAs with partial complementarity to B7 homolog 3 (B7-H3) short hairpin RNA seed region.